MANNKIND CORP Current Assets
MANNKIND CORP (MNKD) had Current Assets of $245.71 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-05
- 2026-06-30: Assets, Current $245.71M.
- 2026-03-31: Assets, Current $251.16M.
- 2025-12-31: Assets, Current $291.58M.
- 2025-09-30: Assets, Current $358.84M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $245.71M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $251.16M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $291.58M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $358.84M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $279.03M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $273.74M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $268.31M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $327.66M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $325.94M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $383.10M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $373.39M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $225.57M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $230.23M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $223.30M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $234.90M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $218.38M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $193.48M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $184.26M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $219.49M 10-K · filed 2023-02-23 | $219.74M 10-K · filed 2022-02-24 |
| 2021-09-30 | $159.21M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $179.90M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $288.34M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $79.48M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $66.35M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $72.58M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $49.35M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $60.76M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $61.74M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $49.83M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $69.69M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $81.85M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $19.52M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $35.80M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $35.03M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $57.22M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $28.63M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $50.93M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $56.09M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $77.49M 10-K · filed 2018-02-27 | |
| 2016-09-30 | $48.60M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $90.76M 10-Q/A · filed 2016-08-10 | |
| 2016-03-31 | $44.14M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $76.65M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $71.24M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $145.83M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $158.29M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $201.15M 10-K · filed 2016-03-15 | |
| 2014-09-30 | $193.52M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $44.91M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $39.40M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $76.28M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $99.33M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $32.16M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $32.28M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $66.81M 10-K · filed 2014-03-03 | |
| 2012-09-30 | $23.20M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $50.34M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $59.71M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $5.82M 10-K · filed 2013-03-18 | |
| 2011-09-30 | $27.02M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $26.86M 10-Q · filed 2011-08-04 | |
| 2010-12-31 | $73.95M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |